NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

思覺失調症:至2030年的流行病學預測

Schizophrenia - Epidemiology Forecast to 2030

出版商 DelveInsight Business Research LLP 商品編碼 963738
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 10個工作天內
價格
思覺失調症:至2030年的流行病學預測 Schizophrenia - Epidemiology Forecast to 2030
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

世界主要7個國家(美國,歐洲5個國家(德國,法國,義大利,西班牙,英國),日本)的思覺失調症的總患病人數,2017年成為了561萬6,463人。這些病例,在調查期間中(2017年∼2030年)預計逐漸增加。 用2017年的年齡層最高的的是35∼44歲,是49萬4,957人。

本報告提供世界主要7個國家的思覺失調症的流行病學的相關調查,國家、性別、年齡、重病度的盛行率,至2030年的流行病學預測等資訊。

目錄

第1章 重要的洞察

第2章 摘要整理

第3章 病的背景和概要

  • 簡介
  • 思覺失調症的早期警告簽字與症狀
  • 思覺失調症的危險因素
  • 思覺失調症的亞型
  • 思覺失調症的機制
  • 思覺失調症的遺傳學
  • 診斷
  • 鑑別診斷

第4章 流行病學和患者人口

  • 主要調查結果
  • KOL的見解
  • 流行病學調查手法
  • 主要7個國家的思覺失調症的整體盛行率
  • 主要7個國家的思覺失調症的確診的整體盛行率

第5章 美國流行病學

  • 前提條件與理論的根據
  • 美國的思覺失調症的盛行率
  • 美國的思覺失調症的盛行率和確診的病例
  • 性別:確診的美國的思覺失調症的盛行率
  • 各年齡:確診的美國思覺失調症的盛行率
  • 各重症度:確診的美國思覺失調症的盛行率

第6章 流行病學歐洲5個國家

第7章 日本流行病學

第8章 附錄

  • 參考文件
  • 報告的調查手法

第9章 DelveInsight的服務內容

第10章 免責聲明

第11章 關於DelveInsight

目錄
Product Code: DIEI0009

DelveInsight's 'Schizophrenia-Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted schizophrenia epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Schizophrenia Understanding

Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning, and can be disabling.

Schizophrenia is typically diagnosed in the late teen years to the early thirties and tends to emerge earlier in males (late adolescence - early twenties) than females (early twenties - early thirties). A diagnosis of schizophrenia often follows the first episode of psychosis, when individuals first display symptoms of schizophrenia. Gradual changes in thinking, mood, and social functioning often begin before the first episode of psychosis, usually starting in mid-adolescence. Schizophrenia can occur in younger children, but it is rare for it to occur before late adolescence. The most common form is paranoid schizophrenia, or schizophrenia with paranoia, as it's often called. People with paranoid schizophrenia have an altered perception of reality. They may see or hear things that don't exist, speak in strange or confusing ways, believe that others are trying to harm them, or feel like they're being constantly watched. This can cause relationship problems, disrupt normal daily activities like bathing, eating, or running errands, and lead to alcohol and drug abuse in an attempt to self-medicate.

Schizophrenia Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of schizophrenia, Diagnosed Prevalent cases of schizophrenia, Gender-specific Diagnosed Prevalent cases of schizophrenia, Age-specific Diagnosed Prevalent cases of schizophrenia, Severity-specific Diagnosed Prevalent cases of schizophrenia scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Schizophrenia Detailed Epidemiology Segmentation

  • Total prevalent population of schizophrenia in the 7MM was 5,616,463 in 2017. These cases of schizophrenia in the 7MM is expected to increase throughout the study period, i.e., 2017-2030.
  • Total diagnosed prevalent population of schizophrenia in the 7MM was observed to be 3,811,974 in 2017.
  • Among the European five countries, Germany has the highest diagnosed prevalent population followed by the United Kingdom and France. On the other hand, Spain had the lowest diagnosed prevalent population.
  • In the epidemiology model of schizophrenia, there are multiple age groups referred ranging from 18-24 Years; 25-34 Years; 35-44 Years; 45-54 Years; 55-64 Years and 65+ Years for schizophrenia in the US. The highest was 494,957 in the age group 35-44 Years, in 2017.
  • Men with schizophrenia appear to have more negative symptoms and more severe clinical features than females, particularly in social withdrawal, substance abuse, and blunted or incongruent affects than female patients.
  • In 2017, the diagnosed prevalent population of mild schizophrenia was 423,114, which accounted for 22.00% of the total diagnosed cases of schizophrenia, in the United States.

Scope of the Report:

  • The report covers the descriptive overview of schizophrenia, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of schizophrenia.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of schizophrenia, Total Diagnosed and Treated Cases of schizophrenia.

Report Highlights:

  • Eleven-Year Forecast of schizophrenia
  • 7MM Coverage
  • Prevalent Cases of schizophrenia in 7MM
  • Diagnosed Prevalent cases of schizophrenia in 7MM
  • Gender-specific Diagnosed Prevalent cases of schizophrenia in 7MM
  • Age-specific Diagnosed Prevalent cases of schizophrenia in 7MM
  • Severity-specific Diagnosed Prevalent cases of schizophrenia in 7MM

Key Questions Answered

  • What is the disease risk, burden and unmet needs of schizophrenia?
  • What is the historical schizophrenia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of schizophrenia at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to schizophrenia?
  • Out of the countries mentioned above, which country would have the highest prevalent population of schizophrenia during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to buy:

The schizophrenia report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM schizophrenia market.
  • Quantify patient populations in the 7MM schizophrenia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the specific type of schizophrenia that presents the best opportunities for schizophrenia therapeutics in each of the markets covered.
  • The schizophrenia epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The schizophrenia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1. Key Insights

2. Executive Summary of Schizophrenia

3. Disease Background and Overview: Schizophrenia

  • 3.1. Introduction
  • 3.2. Early warning signs and symptoms of schizophrenia
  • 3.3. Risk factors of schizophrenia
  • 3.4. Subtypes of schizophrenia
  • 3.5. Mechanism of schizophrenia
  • 3.6. Genetics of schizophrenia
  • 3.7. Diagnosis
  • 3.8. Differential Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. KOL Views
  • 4.3. Epidemiology Methodology
  • 4.4. Total Prevalent Cases of Schizophrenia in the 7MM
  • 4.5. Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Prevalent Cases of schizophrenia in the United States
  • 5.3. Diagnosed Prevalent cases of schizophrenia in the United States
  • 5.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in the United States
  • 5.5. Age-specific Diagnosed Prevalent cases of schizophrenia in the United States
  • 5.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in the United States

6. EU5 Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Prevalent Cases of schizophrenia in Germany
    • 6.1.3. Diagnosed Prevalent cases of schizophrenia in Germany
    • 6.1.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in Germany
    • 6.1.5. Age-specific Diagnosed Prevalent cases of schizophrenia in Germany
    • 6.1.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Assumptions and Rationale
    • 6.2.2. Prevalent Cases of schizophrenia in France
    • 6.2.3. Diagnosed Prevalent cases of schizophrenia in France
    • 6.2.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in France
    • 6.2.5. Age-specific Diagnosed Prevalent cases of schizophrenia in France
    • 6.2.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Prevalent Cases of schizophrenia in Italy
    • 6.3.3. Diagnosed Prevalent cases of schizophrenia in Italy
    • 6.3.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in Italy
    • 6.3.5. Age-specific Diagnosed Prevalent cases of schizophrenia in Italy
    • 6.3.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Prevalent Cases of schizophrenia in Spain
    • 6.4.3. Diagnosed Prevalent cases of schizophrenia in Spain
    • 6.4.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in Spain
    • 6.4.5. Age-specific Diagnosed Prevalent cases of schizophrenia in Spain
    • 6.4.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Prevalent Cases of schizophrenia in the UK
    • 6.5.3. Diagnosed Prevalent cases of schizophrenia in the UK
    • 6.5.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in the UK
    • 6.5.5. Age-specific Diagnosed Prevalent cases of schizophrenia in the UK
    • 6.5.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in the UK

7. Japan Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Prevalent Cases of schizophrenia in Japan
  • 7.3. Diagnosed Prevalent cases of schizophrenia in Japan
  • 7.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in Japan
  • 7.5. Age-specific Diagnosed Prevalent cases of schizophrenia in Japan
  • 7.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in Japan

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

  • Table 1 Summary of Schizophrenia, Epidemiology and Key Events (2017-2030)
  • Table 2 Early symptoms of schizophrenia
  • Table 3 Symptoms of Schizophrenia
  • Table 4 Clinical features of schizophrenia, bipolar disorder, schizoaffective disorder, autism, and ADHD
  • Table 5 Total Prevalent Cases of Schizophrenia in the 7MM (2017-2030)
  • Table 6 Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM (2017-2030)
  • Table 7 Prevalent cases of schizophrenia in the United States (2017-2030)
  • Table 8 Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Table 9 Gender-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Table 10 Age-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Table 11 Severity-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Table 12 Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 13 Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 14 Gender-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 15 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 16 Severity-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 17 Prevalent cases of schizophrenia in France (2017-2030)
  • Table 18 Diagnosed Prevalent cases of schizophrenia in France (2017-2030)
  • Table 19 Gender-specific Diagnosed Prevalent cases of schizophrenia in France (2017-2030)
  • Table 20 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 21 Severity-specific Diagnosed Prevalent cases of schizophrenia in France (2017-2030)
  • Table 22 Prevalent cases of schizophrenia in Italy (2017-2030)
  • Table 23 Diagnosed Prevalent cases of schizophrenia in Italy (2017-2030)
  • Table 24 Gender-specific Diagnosed Prevalent cases of schizophrenia in Italy (2017-2030)
  • Table 25 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Table 26 Severity-specific Diagnosed Prevalent cases of schizophrenia in Italy (2017-2030)
  • Table 27 Prevalent cases of schizophrenia in Spain (2017-2030)
  • Table 28 Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Table 29 Gender-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Table 30 Age-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Table 31 Severity-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Table 32 Prevalent cases of schizophrenia in the UK (2017-2030)
  • Table 33 Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Table 34 Gender-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Table 35 Age-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Table 36 Severity-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Table 37 Prevalent cases of schizophrenia in Japan (2017-2030)
  • Table 38 Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)
  • Table 39 Gender-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)
  • Table 40 Age-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)
  • Table 41 Severity-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)

List of Figures

  • Figure 1 Overview of Schizophrenia
  • Figure 2 Interaction of genetic and environmental risk factors in the developmental pathology of schizophrenia
  • Figure 3 Neuron-glia interactions in the cerebral cortex-key neural substrates for the pathology of schizophrenia
  • Figure 4 Schematic representation of drug actions that normalize aberrant glutamate neurotransmission in the prefrontal cortex of schizophrenics
  • Figure 5 A representative molecular pathway for schizophrenia-fine-tuning of the glutamate synapse
  • Figure 6 KOL Views
  • Figure 7 KOL Views
  • Figure 8 Total Prevalent Cases of Schizophrenia in the 7MM (2017-2030)
  • Figure 9 Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM (2017-2030)
  • Figure 10 Prevalent cases of schizophrenia in the United States (2017-2030)
  • Figure 11 Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Figure 12 Gender-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Figure 13 Age-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Figure 14 Severity-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017-2030)
  • Figure 15 Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 16 Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 17 Gender-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 18 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 19 Severity-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 20 Prevalent cases of schizophrenia in France (2017-2030)
  • Figure 21 Diagnosed Prevalent cases of schizophrenia in France (2017-2030)
  • Figure 22 Gender-specific Diagnosed Prevalent cases of schizophrenia in France (2017-2030)
  • Figure 23 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 24 Severity-specific Diagnosed Prevalent cases of schizophrenia in France (2017-2030)
  • Figure 25 Prevalent cases of schizophrenia in Italy (2017-2030)
  • Figure 26 Diagnosed Prevalent cases of schizophrenia in Italy (2017-2030)
  • Figure 27 Gender-specific Diagnosed Prevalent cases of schizophrenia in Italy (2017-2030)
  • Figure 28 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017-2030)
  • Figure 29 Severity-specific Diagnosed Prevalent cases of schizophrenia in Italy (2017-2030)
  • Figure 30 Prevalent cases of schizophrenia in Spain (2017-2030)
  • Figure 31 Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Figure 32 Gender-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Figure 33 Age-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Figure 34 Severity-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017-2030)
  • Figure 35 Prevalent cases of schizophrenia in the UK (2017-2030)
  • Figure 36 Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Figure 37 Gender-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Figure 38 Age-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Figure 39 Severity-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017-2030)
  • Figure 40 Prevalent cases of schizophrenia in Japan (2017-2030)
  • Figure 41 Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)
  • Figure 42 Gender-specific Diagnosed Prevalent cases of schizophrenia in Japan(2017-2030)
  • Figure 43 Age-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)
  • Figure 44 Severity-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017-2030)